- Home
- ANVS vs CEE Comparison
ANVS vs CEE Comparison
Compare ANVS & CEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.22
Company Overview
Basic Information| Metric | ANVS | CEE |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 128.1M |
| IPO Year | 2019 | 1994 |
Fundamental Metrics
Financial Performance| Metric | ANVS | CEE |
|---|---|---|
| Price | $2.22 | $17.69 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $13.50 | N/A |
| AVG Volume (30 Days) | ★ 382.7K | 22.4K |
| Earning Date | 03-16-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $11.20 |
| 52 Week High | $5.50 | $19.98 |
Technical Indicators
Market Signals| Indicator | ANVS | CEE |
|---|---|---|
| Relative Strength Index (RSI) | 38.52 | 43.43 |
| Support Level | $1.97 | $16.95 |
| Resistance Level | $2.29 | $18.35 |
| Average True Range (ATR) | 0.22 | 0.71 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 1.08 | 41.57 |
Price Performance
Historical Comparison ANVS
CEE
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.